REMEGEN(09995.HK): Expected H1 Revenue of Approximately RMB5.85 Billion, YoY Growth of 433%; Return to Profitability

NewTimeSpace News: Remegen (09995.HK) released an inside‑information announcement on 5 August 2026. Based on preliminary calculations by the finance department, the Company expects operating revenue of approximately RMB5.85 billion for H1 2026, an increase of around RMB4.752 billion or 433% YoY, versus RMB1.098 billion recorded in the corresponding period of last year. Net profit attributable to owners of the parent is expected to reach roughly RMB4.7 billion, achieving a return to profitability. Net profit after non‑recurring gains and losses is projected at about RMB4.3 billion, also turning profitable. A net loss of approximately RMB450 million was recorded for the same period of 2025.

Key drivers for the performance change are as follows: sustained growth in domestic sales of core products telitacicept and disitamab vedotin. In addition, the Company entered into an exclusive licensing agreement for RC148 with AbbVie, granting AbbVie exclusive rights for the development, manufacturing and commercialisation of RC148 outside Greater China, which contributed to a sharp surge in technology licensing income.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.